Phenoxybenzamine-d5 (hydrochloride)

Phenoxybenzamine-d5 is intended for use as an internal standard for the quantification of phenoxybenzamine (Cay-16211) by GC- or LC-MS. Phenoxybenzamine is an antagonist of alpha-adrenergic receptors (alpha-ARs). It inhibits norepinephrine-induced inositol phosphate formation in HEK293 cells expressing alpha1-ARs (EC50s = 125.9-316.2 nM), as well as radioligand binding to alpha2A-, alpha2B-, and alpha2C-ARs in CHO cell membranes (Kis = 60, 10, and 60 nM, respectively). Phenoxybenzamine (0.5-5 µM) decreases norepinephrine-, histamine-, and calcium-induced contractions in isolated rabbit aortic strips. It also inhibits proliferation of nine cancer cell lines, including lymphoma, breast, and lung cancer cells, with IC50 values ranging from 29.5 to 99.8 µM. Phenoxybenzamine (3-1,000 µg/kg) reduces increases in diastolic blood pressure induced by the alpha-AR agonists cirazoline (Cay-21791), St-587, Sgd 101/75, and B-HT 920 (Cay-14177) in pithed rats. It also decreases the time to find the platform in the Morris water maze, indicating restored spatial memory, in a rat model of fluid percussion-induced traumatic brain injury (TBI). Formulations containing phenoxybenzamine have been used in the treatment of hypertension and hyperhidrosis associated with pheochromocytomas, an adrenal medullary neuroendocrine tumor.Formal Name: N-benzyl-N-(2-chloroethyl)-1-(phenoxy-d5)propan-2-amine, monohydrochloride. CAS Number: 1329838-45-0. Molecular Formula: C18H17ClD5NO . HCl. Formula Weight: 345.3. Purity: >98% deuterated forms (d1-d5). Formulation: (Request formulation change), A solid. Solubility: DMF: 30 mg/ml, DMF:PBS (pH 7.2) (1:1): 0.3 mg/ml, DMSO: 25 mg/ml, Ethanol: 25 mg/ml. SMILES: [2H]C1=C(OCC(C)N(CC2=CC=CC=C2)CCCl)C([2H])=C([2H])C([2H])=C1[2H].Cl. InChi Code: InChI=1S/C18H22ClNO.ClH/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17,/h2-11,16H,12-15H2,1H3,1H/i3D,6D,7D,10D,11D,. InChi Key: VBCPVIWPDJVHAN-PEEBBJRGSA-N.